Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein

被引:28
作者
Trambas, C
Wang, ZM
Cianfriglia, M
Woods, G
机构
[1] Univ Tasmania, Discipline Pathol, Hobart, Tas, Australia
[2] Ist Super Sanita, I-00161 Rome, Italy
关键词
natural killer cells; P-glycoprotein; dye efflux; Western blot analysis; MDR1;
D O I
10.1046/j.1365-2141.2001.02885.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several lines of evidence including reverse transcription polymerase chain reaction, immunoreactivity and their ability to efflux rhodamine 123 have implied the existence of P-glycoprotein in natural killer (NK) cells. It has been a natural tendency to assume that NK-cell P-glycoprotein is identical to the P-glycoprotein of multidrug resistant (MDR) cell lines, however, the present study uncovered major differences. Functionally, NK cells demonstrated a restricted substrate profile, being unable to transport daunorubicin and calcein acetoxymethylester while efficiently transporting other P-glycoprotein substrates. Furthermore, physical differences in NK-cell P-glycoprotein were established by differential reactivity with P-glycoprotein antibodies. NK cells demonstrated strong reactivity with C494 and JSB-1, but did not react appreciably with C219. In addition, NK cells were unable to bind to the antibody MM4.17 unless they had been fixed and permeabilized, yet this antibody normally recognizes an extracellular epitope of P-glycoprotein. These differences culminated in the demonstration using Western analysis that NK cells did not express detectable levels of 170 kDa P-glycoprotein. Instead, NK cells expressed small-molecular-weight 'mini P-glycoprotein' products, of approximately 70 and 80 kDa. Collectively, these data indicate that the predominant P-glycoprotein species of NK cells are novel mini P-glycoproteins and not the classic P-glycoprotein of MDR models.
引用
收藏
页码:177 / 184
页数:8
相关论文
共 35 条
[11]   DETECTION OF P-GLYCOPROTEIN ISOFORMS BY GENE-SPECIFIC MONOCLONAL-ANTIBODIES [J].
GEORGES, E ;
BRADLEY, G ;
GARIEPY, J ;
LING, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (01) :152-156
[12]   Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP [J].
Germann, UA ;
Ford, PJ ;
Shlyakhter, D ;
Mason, VS ;
Harding, MW .
ANTI-CANCER DRUGS, 1997, 8 (02) :141-155
[13]   BIOCHEMISTRY OF MULTIDRUG-RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER [J].
GOTTESMAN, MM ;
PASTAN, I .
ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 :385-427
[14]   PREFERENTIAL EXPRESSION AND ACTIVITY OF MULTIDRUG RESISTANCE GENE-1 PRODUCT (P-GLYCOPROTEIN), A FUNCTIONALLY ACTIVE EFFLUX PUMP, IN HUMAN CD8+ T-CELLS - A ROLE IN CYTOTOXIC EFFECTOR FUNCTION [J].
GUPTA, S ;
KIM, CH ;
TSURUO, T ;
GOLLAPUDI, S .
JOURNAL OF CLINICAL IMMUNOLOGY, 1992, 12 (06) :451-458
[15]   Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells [J].
Hollo, Z ;
Homolya, L ;
Hegedus, T ;
Sarkadi, B .
FEBS LETTERS, 1996, 383 (1-2) :99-104
[16]  
HOMOLYA L, 1993, J BIOL CHEM, V268, P21493
[17]   IDENTIFICATION OF A P-GLYCOPROTEIN-RELATED PROTEIN (MINI-P-GLYCOPROTEIN) WHICH IS OVEREXPRESSED IN MULTIDRUG-RESISTANT CELLS [J].
KAWAI, K ;
KUSANO, I ;
IDO, M ;
SAKURAI, M ;
SHIRAISHI, T ;
YATANI, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 198 (02) :804-810
[18]   INHIBITION OF CELL-MEDIATED CYTOLYSIS AND P-GLYCOPROTEIN FUNCTION IN NATURAL-KILLER-CELLS BY VERAPAMIL ISOMERS AND CYCLOSPORINE-A ANALOGS [J].
KLIMECKI, WT ;
TAYLOR, CW ;
DALTON, WS .
JOURNAL OF CLINICAL IMMUNOLOGY, 1995, 15 (03) :152-158
[19]  
KLIMECKI WT, 1994, BLOOD, V83, P2451
[20]   EXPRESSION AND FUNCTION OF MULTIDRUG-RESISTANCE P-GLYCOPROTEIN IN A CULTURED NATURAL-KILLER CELL-RICH POPULATION REVEALED BY MRK16 MONOCLONAL-ANTIBODY AND AHC-52 [J].
KOBAYASHI, Y ;
YAMASHIRO, T ;
NAGATAKE, H ;
YAMAMOTO, T ;
WATANABE, N ;
TANAKA, H ;
SHIGENOBU, K ;
TSURUO, T .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (08) :1641-1646